ID
45407
Description
Principal Investigator: Mary V. Relling, Pharm.D., St. Jude Children Research Hospital, Pharmaceutical Sciences Department, Memphis, TN, USA MeSH: Precursor B-Cell Lymphoblastic Leukemia-Lymphoma https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000637 We estimated the plasma clearance of methotrexate from 1279 acute lymphoblastic leukemia (ALL) patients treated on the Children Oncology Group 9904 and 9905 trials (http://clinicaltrials.gov/show/NCT00005585 and http://clinicaltrials.gov/show/NCT00005596). Patients received either a 24-hour infusion of a 1 g/m2 dose or 4-hour infusion of a 2 g/m2 dose). Methotrexate clearance was lower in older children (p=7 x 10-7), females (p=2.7 x 10-4), and patients who received a delayed intensification phase (p=0.0022). In a genome-wide analysis, methotrexate clearance was associated with polymorphisms in the SLCO1B1 gene (p=2.1 x 10-11), which encodes for an organic anion transporter. This replicates findings using different schedules of high-dose methotrexate in ALL patients treated on St. Jude protocols. A combined meta-analysis yields a p-value of 5.7 x 10-19 for the association of methotrexate clearance with SLCO1B1 SNP rs4149056 (Trevino et al, PMID 19901119 and Ramsey et al, PMID 23233662). This data set includes the dependent variable of methotrexate clearance and all of the SNP data available from arrays.
Lien
Mots-clés
Versions (1)
- 19/11/2022 19/11/2022 - Simon Heim
Détendeur de droits
Mary V. Relling, Pharm.D., St. Jude Children Research Hospital, Pharmaceutical Sciences Department, Memphis, TN, USA
Téléchargé le
19 novembre 2022
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
dbGaP phs000637 Methotrexate Clearance GWAS
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, subject source, and subject source ID of participants with acute lymphoblastic leukemia and involved in the "Methotrexate Clearance GWAS in Acute Lymphoblastic Leukemia (ALL) Patients" project.
- Subject ID, sample ID, sample source, sample source ID of participants with acute lymphoblastic leukemia and involved in the "Methotrexate Clearance GWAS in Acute Lymphoblastic Leukemia (ALL) Patients" project.
- Subject ID, protocol used for subject treatment, treatment arm, infusion of methotrexate, average methotrexate clearance, gender, and genetically determined race of participants with acute lymphoblastic leukemia and involved in the "Methotrexate Clearance GWAS in Acute Lymphoblastic Leukemia (ALL) Patients" project.
- Sample ID, body site where sample was collected, analyte type, tumor status of samples, histological type of samples obtained from participants with acute lymphoblastic leukemia and involved in the "Methotrexate Clearance GWAS in Acute Lymphoblastic Leukemia (ALL) Patients" project.
Similar models
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, subject source, and subject source ID of participants with acute lymphoblastic leukemia and involved in the "Methotrexate Clearance GWAS in Acute Lymphoblastic Leukemia (ALL) Patients" project.
- Subject ID, sample ID, sample source, sample source ID of participants with acute lymphoblastic leukemia and involved in the "Methotrexate Clearance GWAS in Acute Lymphoblastic Leukemia (ALL) Patients" project.
- Subject ID, protocol used for subject treatment, treatment arm, infusion of methotrexate, average methotrexate clearance, gender, and genetically determined race of participants with acute lymphoblastic leukemia and involved in the "Methotrexate Clearance GWAS in Acute Lymphoblastic Leukemia (ALL) Patients" project.
- Sample ID, body site where sample was collected, analyte type, tumor status of samples, histological type of samples obtained from participants with acute lymphoblastic leukemia and involved in the "Methotrexate Clearance GWAS in Acute Lymphoblastic Leukemia (ALL) Patients" project.
C0680251 (UMLS CUI [1,2])
C0750484 (UMLS CUI [1,2])
C0349636 (UMLS CUI [1,3])
C0087111 (UMLS CUI [1,2])
C0023449 (UMLS CUI [1,3])